Table 5.
Estimated Free Energy of Binding, H-Bond Interactions and Hydrophobic Interactions between compounds and receptors.
| Targets | Compounds | Pubchem ID | Binding Affinity | Hydrophobic Interactions | Hydrogen bonding |
|---|---|---|---|---|---|
| AR | Ajoene | 5386591 | −4.2 | PRO694,ASN727,PHE826 | GLN693,ASP695 |
| Allixin | 86,374 | −6.3 | LEU704,LEU707,MET749,PHE764,LEU873 | GLY708 | |
| Catechin | 9064 | −8.5 | LEU701,MET745,PHE764,LEU873 | LEU707,LEU873,THR877 | |
| Luteolin | 5,280,445 | −8.3 | VAL684,VAL715,ARG752 | PRO682,GLN711,TRP751,LYS808 | |
| Nigellicine | 11,402,337 | −7.6 | MET745,VAL746,MET749,PHE764,LEU873 | ASN705,GLY708 | |
| Nigellidine | 136,828,302 | −7.5 | ALA748,ARG752,LEU805 | TRP751,ARG752,ASN756 | |
| Nigellimine | 20,725 | −5.5 | GLU706, ASP890 | ASP690, GLU706 | |
| Quercetin | 5,280,343 | −9 | MET745 | LEU704,GLY708,GLN711,MET745,ARG752,LEU873 | |
| Thymoquinone | 10,281 | −6.3 | LEU704,LEU707,VAL746,PHE764,LEU873 | PHE764 | |
| Doxorubicin | 31,703 | −7.1 | LEU881,ILE882,PHE891,ALA896 | HIS885, PHE891 | |
| PIK3R1 | Ajoene | 5386591 | −4.7 | ILE800,TYR836,ILE848,ILE932, | VAL851, SER854 |
| Allixin | 86,374 | −6 | LEU704,LEU707,MET749,PHE764,LEU873 | GLY708 | |
| Catechin | 9064 | −8.5 | LEU701,MET745,PHE764,LEU873 | LEU707,LEU873,THR877 | |
| Luteolin | 5,280,445 | −8.5 | VAL684,VAL715,ARG752 | PRO682,GLN711,TRP751,LYS808 | |
| Nigellicine | 11,402,337 | −7.4 | MET745,VAL746,MET749,PHE764,LEU873 | ASN705,GLY708 | |
| Nigellidine | 136,828,302 | −8.1 | ALA748,ARG752,LEU805 | TRP751,ARG752,ASN756 | |
| Nigellimine | 20,725 | −6.5 | GLU706,ASP890 | ASP690, GLU706 | |
| Quercetin | 5,280,343 | −8.4 | MET745 | LEU704,GLY708,GLN711,MET745,ARG752 | |
| Thymoquinone | 10,281 | −6.2 | LEU704,LEU707,VAL746,PHE764,LEU873 | PHE764 | |
| Doxorubicin | 31,703 | −9.5 | TRP780,ILE800,ILE848,VAL850,ASN920,ILE932,ASP933 | SER774,GLU849,VAL851,GLN859,ASP933 |